ABT-263 (Navitoclax)
产品编号: DC4127
Featured
我们的合作伙伴:
中国地区超过5000个高品质化合物库存
应用领域
Navitoclax (ABT-263) 是有效，可口服的 Bcl-2 抑制剂，可与Bcl-xL，Bcl-2， Bcl-w等多种Bcl-2家族蛋白结合，Ki 值小于 1 nM。
| Cas No.: |
923564-51-6 |
| 名称: |
|
| 别名: |
ABT263,ABT-263 |
| SMILES: |
CC1(CCC(=C(C1)CN2CCN(CC2)C3=CC=C(C=C3)C(=O)NS(=O)(=O)C4=CC(=C(C=C4)N[C@H](CCN5CCOCC5)CSC6=CC=CC=C6)S(=O)(=O)C(F)(F)F)C7=CC=C(C=C7)Cl)C |
| 分子式: |
C47H55ClF3N5O6S3 |
| 分子量: |
974.61 |
| 纯度: |
|
| 保存条件: |
2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
| Description: |
|
| In Vivo: |
|
| In Vitro: |
|
| References: |
ABT-263 (Navitoclax) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM.
in vitro: ABT-263 displays the protection afforded by overexpression of Bcl-2 or Bcl-xL with EC50 values of 60 nM and 20 nM, respectively. A wide r |
| Kinase Assay: |
|
| Cell Assay: |
|
| Animal Administration: |
|
| References: |
|
MSDS
COA
| LOT NO. |
DOWNLOAD |
|
|
| 2018-0101 |
|
询盘
